Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Diluted EPS of $4.30 per share (loss) for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$4.30 | +99.9% |
| 2024 | -$5756.41 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.03 | +99.9% | +99.9% |
| September 30, 2024 | -$1562.18 | — | — |
- BridgeBio Oncology Therapeutics, Inc. showed an increase of +99.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, BridgeBio Oncology Therapeutics, Inc.’s diluted eps has grown by 99.9% (from $5756.41 per share (loss) to $4.30 per share (loss)).
- The most recent figure is from BridgeBio Oncology Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: